Researchers discover underlying mechanisms of skin hardening syndromes

	Tweet

Researchers from Boston University School of Medicine (BUSM) have discovered new details about the underlying mechanisms of skin hardening syndromes. The team connected pharmacological properties of the Novartis Pharma AG drug called balicatib to the skin disorder for the first time after investigating adverse reactions suffered by patients participating in a clinical trial for the treatment of osteoporosis. These findings appear online in the Journal of the American Academy of Dermatology.

Balicatib was developed recently as an osteoporosis drug that can inhibit CathepsinK (catK), an enzyme involved with bone degradation. In a recent trial however, several patients on balicatib experienced hardening of the skin, most frequently around the neck, chest and abdomen. After examining the cases and relating them to recent reports of cathepsin K expression in the skin and the role of cathepsin K in degrading collagen and elastin, the investigators determined that the changes were a direct effect of the drug.

This case study adds a new class of medication to the short list of agents that induce skin hardening syndromes. It also proves that catK affects the skin as well as bones, and marks the first time that skin hardening can be convincingly linked to the pharmacologic properties of a drug.

"This observation emphasizes the importance of intracellular collagen degradation in the skin, a pathway so far vastly underappreciated,” said Thomas Ruenger, MD, PhD, a professor and vice-chair of dermatology at BUSM. “This observation also sheds new light on our understanding of the mechanisms involved in morphea, or skin hardening. Failed collagen degradation has so far not been thought to cause morphea.”

The researchers believe these findings have far-reaching implications for osteoporosis patients and those suffering from skin hardening syndromes.

###

DISCLAIMER: Dr. Ruenger served on the independent data safety monitoring board that monitored the clinical trial in which the described observations were made.

###

Contact: Nathan Bliss

617-638-8490
Boston University Medical Center

RELATED STORIES:
Talk to teens, young adults about sun safety: panel   Cell transplants restore lost skin color   Black women’s hair loss tied to braiding, weaving   Amgen arthritis drug wins U.S. okay for psoriasis   More sore throats in people on acne medication   Many ignore indoor tanning risks   Psoriasis tied to depression, suicide   Spring Into Sunny Weather but Stay Sun Safe   Psoriasis: Newly Diagnosed   Eye color may indicate risk for serious skin conditions   Frequent Hand Washing Puts Health Care Workers at Increased Risk for Irritant Contact Dermatitis   Pedicure Bacteria Problem Worries Health Officials

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]